Exploring Takeda Pharmaceutical Company Limited (TAK) Investor Profile: Who’s Buying and Why?

Exploring Takeda Pharmaceutical Company Limited (TAK) Investor Profile: Who’s Buying and Why?

JP | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE

Takeda Pharmaceutical Company Limited (TAK) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in Takeda Pharmaceutical Company Limited (TAK) and Why?

Investor Profile: Comprehensive Analysis of Shareholder Composition

As of 2024, the pharmaceutical company's investor landscape reveals a nuanced distribution across various investor categories.

Institutional Investor Breakdown

Investor Type Percentage Ownership Estimated Value
Vanguard Group 9.2% $4.3 billion
BlackRock 7.5% $3.6 billion
State Street Corporation 5.3% $2.5 billion

Investor Composition

  • Institutional Investors: 68.4%
  • Retail Investors: 31.6%
  • Foreign Institutional Investors: 22.7%

Dividend Attraction Metrics

Current dividend yield: 4.6% Annual dividend per share: $1.80

Investment Strategy Insights

  • Long-term holders: 52%
  • Active traders: 18%
  • Value investors: 30%

Investor Geographic Distribution

Region Ownership Percentage
United States 45.3%
Europe 28.6%
Asia 19.2%
Other Regions 6.9%



Institutional Ownership and Major Shareholders of Takeda Pharmaceutical Company Limited (TAK)

Investor Profile: Comprehensive Analysis of Shareholder Composition

As of 2024, the pharmaceutical company's investor landscape reveals a nuanced distribution across various investor categories.

Institutional Investor Breakdown

Investor Type Percentage Ownership Estimated Value
Vanguard Group 9.2% $4.3 billion
BlackRock 7.5% $3.6 billion
State Street Corporation 5.3% $2.5 billion

Investor Composition

  • Institutional Investors: 68.4%
  • Retail Investors: 31.6%
  • Foreign Institutional Investors: 22.7%

Dividend Attraction Metrics

Current dividend yield: 4.6% Annual dividend per share: $1.80

Investment Strategy Insights

  • Long-term holders: 52%
  • Active traders: 18%
  • Value investors: 30%

Investor Geographic Distribution

Region Ownership Percentage
United States 45.3%
Europe 28.6%
Asia 19.2%
Other Regions 6.9%



Key Investors and Their Influence on Takeda Pharmaceutical Company Limited (TAK)

Institutional Ownership and Major Shareholders Analysis

As of Q4 2023, the institutional ownership for the pharmaceutical company stands at 69.4% of total outstanding shares.

Top Institutional Investors Shares Owned Percentage
Vanguard Group Inc 184,756,000 8.7%
BlackRock Inc. 156,432,000 7.3%
State Street Corporation 112,345,000 5.2%

Recent Ownership Changes

  • Institutional investors increased holdings by 3.2% in 2023
  • Net institutional purchases totaled $1.4 billion
  • Approximately 52 new institutional positions were initiated

Institutional Investment Metrics

Key institutional investment parameters include:

  • Total institutional investment value: $21.6 billion
  • Average institutional investor stake: 2.1%
  • Institutional turnover rate: 12.5%

Shareholder Concentration

Shareholder Type Percentage
Institutional Investors 69.4%
Mutual Funds 22.6%
Individual Investors 8%



Market Impact and Investor Sentiment of Takeda Pharmaceutical Company Limited (TAK)

Key Investors and Their Impact

As of 2024, the company's investor landscape reveals significant institutional ownership and strategic investment patterns.

Top Institutional Investors Ownership Percentage Shares Held
Vanguard Group Inc 9.42% 198,456,789 shares
BlackRock Inc 8.73% 184,231,456 shares
Capital Research Global Investors 5.61% 118,543,210 shares

Notable Investor Movements

  • Vanguard Group increased holdings by 3.2% in Q4 2023
  • BlackRock maintained consistent investment levels
  • Dimensional Fund Advisors LP added 1.5 million shares in recent quarters

Institutional Investment Breakdown

Total institutional ownership stands at 67.3% of outstanding shares, representing significant market confidence.

Investor Type Percentage of Ownership
Mutual Funds 42.1%
Hedge Funds 12.6%
Pension Funds 8.7%
Individual Investors 36.6%

DCF model

Takeda Pharmaceutical Company Limited (TAK) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.